An interventional study of Pacemaker Rate in Cardiac Amyloidosis and Pacemaker, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by University of Minnesota · Not applicable, Interventional, and Supportive care
This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.
122 studies on the registry are indexed under Amyloid Neuropathies, Familial; 71 are open to participants now.
This study's planned enrollment of 10 is below the median of 60 across 61 interventional studies indexed under Amyloid Neuropathies, Familial.
Browse Amyloid Neuropathies, Familial studies →University of Minnesota is the lead sponsor of 1,184 studies on the registry; 195 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 91 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction.
Other: Pacemaker Rate
CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction.
Kansas City Cardiomyopathy Questionnaire Score
75-100 representing good to excellent health, and 0-24 representing very poor to poor health
Time frame: Month 4
Composite of any cardiovascular event
admission or urgent visit for heart failure and atrial fibrillation, myocardial infarction or stroke
Time frame: Month 4
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyloid Neuropathies, Familial→
University of Minnesota